Commercialisation for Investors

Partnership Opportunities for Industry

We have a portfolio of novel and exciting innovations with a range of investment, licensing and partnership opportunities. Our database is derived from a broad range of research disciplines, containing new innovations and capabilities here at QUT.

View some of our current initiatives.

In 2009, QUT was in the top 25% of Australian universities for:

  • patents granted
  • consulting contracted income.

We have started a number of start-up companies, including:

  • Adalta Pty Ltd
  • Rail Innovation Australia Pty Ltd.

Publicly listed companies on the ASX include:

  • Tissue Therapies Ltd: key technologies in novel growth factors and autologous cell therapies for wound healing, tissue repair and cell culture applications.
  • Impedimed Ltd: medical device company focusing on developing and manufacturing non-invasive medical devices using bioimpedance for lymphoedema and body composition (FDA, CE approvals).
  • Agenix Ltd: commercialising monoclonal antibody diagnostics (first University spinoff in 1982 as MabCo; lead candidate is its high-technology blood clot-imaging agent, ThromboView.
  • Evogenix Ltd: offers a fully integrated approach to creating novel antibody products, rapidly converting non-human antibodies to a potent fully humanized product (acquired by Peptech in 2007 for $152 MM, now Arana Therapeutics).
  • PanBio Ltd: markets a wide range of invitro diagnostic tests that are used by hospitals, pathology laboratories and research institutions (acquired by Inverness Medical).
  • Farmacule Bioindustries Pty Ltd: molecular farming company aimed at cost effectively mass producing high-value industrial and therapeutic proteins and biofuels.

The information contained on this website is for information purposes only. It does not constitute nor is it intended to constitute the provision of financial product advice. Neither bluebox nor any of the other companies named on this site warrant that the information is accurate or complete. The information has been prepared on a best endeavours basis. Investors must undertake their own due diligence and make their own assumptions on the prospects of any investment opportunity described on this site.

bluebox is the holder of an Australian Financial Services Licence, number 313609.